Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

Phase 3 Not yet recruiting 136 enrolled Chengdu Kangnuoxing Biopharma,Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.

Timeline

Start: 2026-08
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM310	Monoclonal antibody	—	Subcutaneous

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

Summary

Timeline

Drugs

Indications